With respect to the newness criterion, according to the applicant, TECVAYLI TM was granted BLA approval from FDA on October 25, 2022 for the treatment of adult patients with RRMM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Consequently, this could improve cellular function by regulating cellular events, such as cytokine production, cell proliferation, synthesis of DNA and proteins, etc
[2] Some individuals do experience gastrointestinal side effects when taking B12 supplements, particularly when first beginning supplementation
Duration of melasma ranged from 2-10 years with a meanSD of 5.72.51 years
Available from: 71.Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P